首页> 外文期刊>JAMA: the Journal of the American Medical Association >Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.
【24h】

Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.

机译:锯棕榈提取物剂量增加对下尿路症状的影响:一项随机试验。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Saw palmetto fruit extracts are widely used for treating lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH); however, recent clinical trials have questioned their efficacy, at least at standard doses (320 mg/d). OBJECTIVE: To determine the effect of saw palmetto extract (Serenoa repens, from saw palmetto berries) at up to 3 times the standard dose on lower urinary tract symptoms attributed to BPH. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, multicenter, placebo-controlled randomized trial at 11 North American clinical sites conducted between June 5, 2008, and October 10, 2010, of 369 men aged 45 years or older, with a peak urinary flow rate of at least 4 mL/s, an American Urological Association Symptom Index (AUASI) score of between 8 and 24 at 2 screening visits, and no exclusions. INTERVENTIONS: One, 2, and then 3 doses (320 mg/d) of saw palmetto extract or placebo, with dose increases at 24 and 48 weeks. MAIN OUTCOME MEASURES: Difference in AUASI score between baseline and 72 weeks. Secondary outcomes included measures of urinary bother, nocturia, peak uroflow, postvoid residual volume, prostate-specific antigen level, participants' global assessments, and indices of sexual function, continence, sleep quality, and prostatitis symptoms. RESULTS: Between baseline and 72 weeks, mean AUASI scores decreased from 14.42 to 12.22 points (-2.20 points; 95% CI, -3.04 to -0.36) with saw palmetto extract and from 14.69 to 11.70 points (-2.99 points; 95% CI, -3.81 to -2.17) with placebo. The group mean difference in AUASI score change from baseline to 72 weeks between the saw palmetto extract and placebo groups was 0.79 points favoring placebo (upper bound of the 1-sided 95% CI most favorable to saw palmetto extract was 1.77 points, 1-sided P = .91). Saw palmetto extract was no more effective than placebo for any secondary outcome. No clearly attributable adverse effects were identified. CONCLUSION: Increasing doses of a saw palmetto fruit extract did not reduce lower urinary tract symptoms more than placebo. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00603304.
机译:背景:锯棕榈果实提取物被广泛用于治疗归因于前列腺增生(BPH)的下尿路症状。但是,最近的临床试验至少在标准剂量(320 mg / d)时质疑其功效。目的:确定最高剂量为标准剂量3倍的锯棕榈提取物(锯棕榈果实中的Serenoa repens)对BPH引起的下尿路症状的影响。设计,地点和参与者:2008年6月5日至2010年10月10日在北美的11个临床场所进行的一项双盲,多中心,安慰剂对照的随机试验,研究对象为369名年龄在45岁以上的男性,尿液流速至少为4 mL / s,2次筛查时美国泌尿科协会症状指数(AUASI)评分在8至24之间,无排除。干预措施:一,二,三剂(320 mg / d)的锯棕榈提取物或安慰剂,剂量在24和48周时增加。主要观察指标:基线和72周之间AUASI评分的差异。次要结局包括尿频,夜尿,尿流峰值,术后残余量,前列腺特异性抗原水平,参与者的整体评估以及性功能,节制,睡眠质量和前列腺炎症状的指标。结果:从基线到72周,锯棕榈提取物的平均AUASI得分从14.42降低到12.22分(-2.20分; 95%CI,-3.04降低到-0.36),从14.69降低到11.70分(-2.99分; 95%CI) ,-3.81至-2.17)。锯棕榈提取物与安慰剂组之间从基线到72周的AUASI评分变化的组平均差异为0.79分(有利于安慰剂)(最有利于锯棕榈提取物的1面95%CI的上限为1.77点,1面P = .91)。锯棕榈提取物对任何次要结局均不比安慰剂有效。没有明确归因于不良反应。结论:增加锯棕榈果实提取物的剂量并没有比安慰剂减少下尿路症状。试验注册:clinicaltrials.gov标识符:NCT00603304。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号